The trading window has been closed from March 31, 2026 to May 31, 2026 (both days inclusive) for the approval of Audited Financial Results for the quarter and year ended March 31, 2026
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has informed stock exchanges that its Board meeting will be held on May 29, 2026 to consider and approve the Standalone and Consolidated Audited Financial Results for Q4 and FY ended March 31, 2026. The meeting will also consider dividend recommendations for shareholders. The company has closed the trading window from March 31, 2026 to May 31, 2026 (both days inclusive) for directors and designated persons, as per SEBI Insider Trading regulations. This closure is specifically for the approval process of the audited financial results.
The trading window closure is a routine compliance measure under SEBI regulations, preventing insiders from trading shares while unpublished price-sensitive information (financial results) is being prepared. Investors should expect the Q4 and FY 2026 results announcement shortly after the May 29 board meeting, which could impact the stock price.